SynthesisThe pharmacogenomics journal2017
A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.
Synthesis in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.The pharmacogenomics journal · 2018Trial
- An integrated Biobank in the Swedish Heart Failure Registry-clinomics, proteomics, transcriptomics and genomics.ESC heart failure · 2026Observational
- A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress.European journal of clinical pharmacology · 2025Article
- Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.ACS omega · 2020Article
- Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2020Article
- Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.The Journal of pediatrics · 2019Article
- Diuretic Resistance in Heart Failure.Current heart failure reports · 2019Review
- Association of APOL1 With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women.JAMA cardiology · 2018Observational
- Association BetweenJournal of the American Heart Association · 2017Article
- Practical Pharmacogenomic Approaches to Heart Failure Therapeutics.Current treatment options in cardiovascular medicine · 2016Review
- Vascular homeostasis at high-altitude: role of genetic variants and transcription factors.Pulmonary circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
Abstract
We conducted a meta-analysis of pharmacogenomic substudies of three randomized trials conducted in patients with decompensated heart failure (HF) that were led by National Heart Lung and Blood Institute (NHLBI)-funded HF Network to test the hypothesis that candidate genes modulate net fluid loss and weight change in patients with decompensated HF treated with a furosemide-based diuretic regimen. Although none of the genetic variants previously shown to modulate the effects of loop diuretics in healthy individuals were associated with net fluid loss after 72 h of treatment, a set of rare variants in the APOL1 gene, which codes for apolipoprotein L1 (P=0.0005 in the random effects model), was associated with this end point. Moreover, a common variant in the multidrug resistance protein-4 coding gene (ABCC4, rs17268282) was associated with weight loss with furosemide use (P=0.0001). Our results suggest that both common and rare genetic variants modulate the response to a furosemide-based diuretic regimen in patients with decompensated HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.